

# John Buse

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7048183/john-buse-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512  
papers

86,457  
citations

118  
h-index

291  
g-index

555  
ext. papers

99,940  
ext. citations

11.6  
avg, IF

8.04  
L-index

#	Paper	IF	Citations
512	Islet Autoimmunity is Highly Prevalent and Associated With Diminished BCell Function in Patients With Type 2 Diabetes in the Grade Study.. <i>Diabetes</i> , <b>2022</b> ,	0.9	2
511	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e022376	6	1
510	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac066	1	1
509	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. <i>Drugs - Real World Outcomes</i> , <b>2022</b> , 1	2.2	4
508	A new class of drug in the diabetes toolbox.. <i>Nature Medicine</i> , <b>2022</b> , 28, 901-902	50.5	0
507	Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 789526	5.7	0
506	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , <b>2021</b> ,	16.7	3
505	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2132215	10.4	0
504	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. <i>BMJ Open Diabetes Research and Care</i> , <b>2021</b> , 9,	4.5	2
503	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, e32-e34	14.6	6
502	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 2645-2655	14.6	32
501	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	2
500	Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 42-51	1.9	1
499	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 4273-4279	19.7	16
498	Carbohydrate Intake Prior to Oral Glucose Tolerance Testing. <i>Journal of the Endocrine Society</i> , <b>2021</b> , 5, bvab049	0.4	4
497	Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1677-1680	6.7	1
496	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 139-140	18.1	1

495	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14552	3.5	2
494	Oral Semaglutide Reduces HbA and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1099-1116	3.6	5
493	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. <i>Diabetes Care</i> , <b>2021</b> , 44, 1410-1418	14.6	2
492	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , <b>2021</b> , 44, 1595-1603	14.6	10
491	Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1666-1671	6.7	3
490	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1983-1988	6.7	3
489	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 2262-2272	27.4	33
488	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , <b>2021</b> , 44, 1564-1572	14.6	13
487	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2058-2066	6.7	6
486	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
485	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 46-52	18.1	34
484	Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone. <i>Diabetes Technology and Therapeutics</i> , <b>2021</b> , 23, 70-77	8.1	3
483	The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1365-1375	8.7	12
482	Developing Insulin Delivery Devices with Glucose Responsiveness. <i>Trends in Pharmacological Sciences</i> , <b>2021</b> , 42, 31-44	13.2	11
481	Managing the risks and benefits of clinical research in response to a pandemic. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5,	0.4	1
480	Re-engineering The Clinical Research Enterprise in Response to COVID-19: The Clinical Translational Science Award (CTSA) experience and proposed playbook for future pandemics. <i>Journal of Clinical and Translational Science</i> , <b>2021</b> , 5, e96	0.4	2
479	Metabolic state and gustatory perception shapes dynamic interplay between cortical excitability and motor response. <i>Brain Stimulation</i> , <b>2021</b> , 14, 202-205	5.1	2
478	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 960-968	14.6	8

477	Experimental increase of blood glucose alters resting state EEG measures of excitation-inhibition balance. <i>Experimental Physiology</i> , <b>2021</b> , 106, 803-811	2.4	1
476	Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery. <i>ACS Nano</i> , <b>2021</b> , 15, 4294-4304	16.7	9
475	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , <b>2021</b> , 44, 2286-2292	14.6	1
474	Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2116901	10.4	37
473	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 723-732	6.1	2
472	Further RISE'ing to the Challenge of Type 2 Diabetes in Youth. <i>Diabetes Care</i> , <b>2021</b> , 44, 1934-1937	14.6	1
471	Efficacy and safety of once-weekly semaglutide 20 mg versus 10 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 563-574	18.1	11
470	The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. <i>Diabetes Care</i> , <b>2021</b> , 44, 2729-2737	14.6	6
469	Causal role of frontal-midline theta in cognitive effort: a pilot study. <i>Journal of Neurophysiology</i> , <b>2021</b> , 126, 1221-1233	3.2	1
468	4300 Evaluation and structure of the pilot funding program at the University of North Carolina CTSA Hub (NC TraCS). <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 72-72	0.4	
467	4299 The University of North Carolina CTSA Hub (NC TraCS) Service Evaluation: Using Customer Feedback to Improve Services. <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 75-75	0.4	
466	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1546-1552	14.6	38
465	The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1690-1695	6.7	7
464	Inpatient Transition to Virtual Care During COVID-19 Pandemic. <i>Diabetes Technology and Therapeutics</i> , <b>2020</b> , 22, 444-448	8.1	55
463	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. <i>Diabetes Care</i> , <b>2020</b> , 43, 1378-1381	14.6	55
462	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , <b>2020</b> , 43, 1695-1703	14.6	65
461	Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , <b>2020</b> , 43, e30-e31	14.6	1
460	Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 579-584	5.7	10

459	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. <i>Diabetes</i> , <b>2020</b> , 69, 771-783	0.9	12
458	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1128-1141	15.1	25
457	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , <b>2020</b> , 141, 1360-1370	16.7	8
456	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 276-288	4.6	5
455	Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. <i>Diabetes Care</i> , <b>2020</b> , 43, 940-947	14.6	6
454	A Special Thanks to the Reviewers of Diabetes Care. <i>Diabetes Care</i> , <b>2020</b> , 43, 939-939	14.6	78
453	Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	4
452	Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, e108-e110	14.6	17
451	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2193-2198	6.7	5
450	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2026-2034	12.3	9
449	Glucose-Responsive Systems: Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation (Adv. Mater. 13/2020). <i>Advanced Materials</i> , <b>2020</b> , 32, 2070102	24	1
448	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2241-2247	6.7	7
447	Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1537-1547	6.7	22
446	Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	7
445	21-LB: Derived Time-in-Range Is Associated with MACE in T2D: Data from the DEVOTE Trial. <i>Diabetes</i> , <b>2020</b> , 69, 21-LB	0.9	4
444	957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program. <i>Diabetes</i> , <b>2020</b> , 69, 957-P	0.9	1
443	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 2160-PUB	0.9	
442	122-LB: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 122-LB	0.9	

441	123-LB: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose. <i>Diabetes</i> , <b>2020</b> , 69, 123-LB	0.9	
440	Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. <i>Nature Biomedical Engineering</i> , <b>2020</b> , 4, 499-506	19	166
439	Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 398-404	14.6	11
438	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , <b>2020</b> , 11, 53-70	3.6	12
437	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , <b>2020</b> , 43, 643-652	14.6	19
436	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2020</b> , 63, 221-228	10.3	235
435	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2020</b> , 43, 487-493	14.6	483
434	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 446-452	14.6	31
433	Evidence for gene-smoking interactions for hearing loss and deafness in Japanese American families. <i>Hearing Research</i> , <b>2020</b> , 387, 107875	3.9	3
432	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2248-2256	6.7	2
431	The trials and tribulations of determining HbA targets for diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 717-730	15.2	13
430	Real-world evidence: the devil is in the detail. <i>Diabetologia</i> , <b>2020</b> , 63, 1694-1705	10.3	11
429	Dual self-regulated delivery of insulin and glucagon by a hybrid patch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 29512-29517	11.5	29
428	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2487-2492	6.7	11
427	Comprehensive Pulmonary Safety Review of Inhaled Technosphere Insulin in Patients with Diabetes Mellitus. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 973-983	3.2	7
426	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	5
425	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107706	3.2	0
424	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 810-811	18.1	2

423	Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. <i>Pharmacology Research and Perspectives</i> , <b>2020</b> , 8, e00637	3.1	5
422	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. <i>Diabetes Care</i> , <b>2020</b> , 43, 2121-2127	14.6	5
421	Bibliometrics approach to evaluating the research impact of CTSA: A pilot study. <i>Journal of Clinical and Translational Science</i> , <b>2020</b> , 4, 336-344	0.4	5
420	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120970933 <sup>3,3</sup>		1
419	Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation. <i>Advanced Materials</i> , <b>2020</b> , 32, e1902004	24	87
418	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCel trial. <i>Cardiovascular Diabetology</i> , <b>2019</b> , 18, 138	8.7	25
417	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. <i>Diabetes Care</i> , <b>2019</b> , 42, 2065-2074	14.6	4
416	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , <b>2019</b> , 21, 682-690	8.1	2
415	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2262-2271 <sup>146</sup>		82
414	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , <b>2019</b> , 394, 559	40	1
413	A Mixed-Methods, Randomized Clinical Trial to Examine Feasibility of a Mindfulness-Based Stress Management and Diabetes Risk Reduction Intervention for African Americans with Prediabetes. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2019</b> , 2019, 3962623	2.3	10
412	Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1223-1236	6.7	24
411	Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 632-639	2.6	9
410	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. <i>Diabetes</i> , <b>2019</b> , 68, 1649-1662	0.9	15
409	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. <i>Diabetes Care</i> , <b>2019</b> , 42, e89-e91	14.6	4
408	Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2203-2210 <sup>67</sup>		41
407	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology, the</i> , <b>2019</b> , 7, 528-539	18.1	105
406	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2096-2106	6.7	5

405	Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. <i>Pediatric Diabetes</i> , <b>2019</b> , 20, 556-566	3.6	3
404	Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10744-10748	11.5	26
403	Evidence supports prediabetes treatment. <i>Science</i> , <b>2019</b> , 364, 341-342	33.3	16
402	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , <b>2019</b> , 42, 1075-1080	14.6	7
401	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , <b>2019</b> , 42, 919-930	14.6	37
400	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1745-1751	6.7	15
399	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1625-1633	6.7	14
398	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1437-1444	6.7	9
397	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , <b>2019</b> , 42, 1147-1154	14.6	138
396	Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2019</b> , 76, 526-535	17.2	42
395	Identifying individual risk rare variants using protein structure guided local tests (POINT). <i>PLoS Computational Biology</i> , <b>2019</b> , 15, e1006722	5	4
394	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 1912-1920	14.6	19
393	Sa0010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES IA POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34,	4.3	1
392	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) IA POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34,	4.3	1
391	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2450-2458	6.7	6
390	Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. <i>Science Advances</i> , <b>2019</b> , 5, eaaw4357	14.3	62
389	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , <b>2019</b> , 17, 615-627	3.4	5
388	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 98, 104-111	12.7	7



387	Reasons for Increases in Complications of Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1518-1519	27.4	0
386	Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 2219-2230.e6	3.5	4
385	Longitudinal Phenotypes of Type 1 Diabetes in Youth Based on Weight and Glycemia and Their Association With Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 6003-6016	5.6	8
384	Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 1214-1220	16.2	20
383	6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL. <i>Diabetes</i> , <b>2019</b> , 68, 6-LB	0.9	1
382	985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8. <i>Diabetes</i> , <b>2019</b> , 68, 985-P	0.9	6
381	1643-P: Prevalence of Diabetes Medication Regimens in PCORnet, the National Patient-Centered Clinical Research Network. <i>Diabetes</i> , <b>2019</b> , 68, 1643-P	0.9	
380	15-LB: Diabetes Duration Did Not Moderate the Reduction in Severe Hypoglycemia Seen with Degludec vs. Glargine U100 in DEVOTE. <i>Diabetes</i> , <b>2019</b> , 68, 15-LB	0.9	
379	983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7. <i>Diabetes</i> , <b>2019</b> , 68, 983-P	0.9	0
378	1141-P: Detailed Phenotype of Randomized Participants by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes</i> , <b>2019</b> , 68, 1141-P	0.9	
377	8-LB: Outcomes of Type 2 Diabetes (T2D) Clustering Replicated in the DEVOTE Trial. <i>Diabetes</i> , <b>2019</b> , 68, 8-LB	0.9	
376	Characteristics and Delivery of Diabetes Shared Medical Appointments in North Carolina. <i>North Carolina Medical Journal</i> , <b>2019</b> , 80, 261-268	0.6	1
375	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e008018	6	15
374	Glucose-responsive oral insulin delivery for postprandial glycemic regulation. <i>Nano Research</i> , <b>2019</b> , 12, 1539-1545	10	33
373	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 854-865	6.7	5
372	Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	23
371	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. <i>Diabetes Care</i> , <b>2019</b> , 42, e21-e23	14.6	8
370	Advances in transdermal insulin delivery. <i>Advanced Drug Delivery Reviews</i> , <b>2019</b> , 139, 51-70	18.5	119

369	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 423-426	8	22
368	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 525-532	6.7	11
367	Bioresponsive Microneedles with a Sheath Structure for H O and pH Cascade-Triggered Insulin Delivery. <i>Small</i> , <b>2018</b> , 14, e1704181	11	80
366	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1428-1440	0.9	18
365	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. <i>Diabetes Care</i> , <b>2018</b> , 41, 1196-1203	14.6	4
364	Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. <i>ACS Nano</i> , <b>2018</b> , 12, 2466-2473	16.7	132
363	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , <b>2018</b> , 41, 14-31	14.6	263
362	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , <b>2018</b> , 41, 596-603	14.6	44
361	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 105-113	18.1	336
360	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1217-1232	3.6	10
359	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1732-1739	6.7	2
358	Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1467-1470	3	17
357	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 712-721	6.1	20
356	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 129-140	6.7	10
355	Synthetic beta cells for fusion-mediated dynamic insulin secretion. <i>Nature Chemical Biology</i> , <b>2018</b> , 14, 86-93	11.7	110
354	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , <b>2018</b> , 61, 58-65	10.3	98
353	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , <b>2018</b> , 61, 48-57	10.3	101
352	Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution. <i>Pediatrics</i> , <b>2018</b> , 142,	7.4	7

351	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 2229-2235	14.6	40
350	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2522-2533	5.6	4
349	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. <i>Diabetes Care</i> , <b>2018</b> , 41, 1998-2009	14.6	24
348	Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. <i>Diabetes Care</i> , <b>2018</b> , 41, 1557-1559	14.6	3
347	Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. <i>Diabetes Technology and Therapeutics</i> , <b>2018</b> , 20, 571-575	8.1	50
346	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , <b>2018</b> , 138, 1605-1607	16.7	20
345	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1663-1671	14.6	32
344	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , <b>2018</b> , 41, 1783-1791	14.6	63
343	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. <i>Diabetes Care</i> , <b>2018</b> , 41, 1792-1800	14.6	17
342	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2532-2540	6.7	81
341	Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina <b>2018</b> , 2,		3
340	Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2). <i>Diabetes</i> , <b>2018</b> , 67, 1179-P	0.9	2
339	Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1). <i>Diabetes</i> , <b>2018</b> , 67, 212-OR	0.9	4
338	Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM: Real-World Analysis of >700,000 U.S. Patients. <i>Diabetes</i> , <b>2018</b> , 67, 4-LB	0.9	1
337	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , <b>2018</b> , 67, 522-P	0.9	34
336	Latest Developments in Continuous Glucose Monitoring, Insulin, and Adjunctive Treatments in Type 1 Diabetes. <i>US Endocrinology</i> , <b>2018</b> , 14, 54	0.3	
335	Simplici-T1: First Clinical Trial to Test Activation of Glucokinase as an Adjunctive Treatment for Type 1 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 126-LB	0.9	1
334	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 56-OR	0.9	

333	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. <i>Diabetes Care</i> , <b>2018</b> , 41, 348-355	14.6	10
332	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 333-340	14.6	30
331	Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. <i>Diabetes Spectrum</i> , <b>2018</b> , 31, 344-347	1.9	2
330	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 2404-2413	14.6	16
329	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2885-2893	6.7	31
328	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e009304	6	12
327	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2018</b> , 61, 2461-2498	10.3	656
326	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2018</b> , 41, 2669-2701	14.6	1307
325	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1693-1702	6.9	15
324	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , <b>2018</b> , 138, 2884-2894	16.7	50
323	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 2383-2392	3.6	13
322	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. <i>Circulation</i> , <b>2018</b> , 137, 2179-2183	16.7	52
321	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , <b>2018</b> , 41, 1560-1562	14.6	5
320	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 857-866	2.6	6
319	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 1970-1980	14.6	117
318	Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2585-2597	6.7	115
317	Hypoxia and HO Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. <i>Nano Letters</i> , <b>2017</b> , 17, 733-739	11.5	172
316	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 970-978	6.7	16

315	Red Blood Cells for Glucose-Responsive Insulin Delivery. <i>Advanced Materials</i> , <b>2017</b> , 29, 1606617	24	100
314	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , <b>2017</b> , 40, e23-e24	14.6	1
313	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 666-675	2.6	1
312	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. <i>Epidemiology</i> , <b>2017</b> , 28, 446-454	3.1	12
311	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 966-972	14.6	41
310	Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 920-929	11.5	75
309	Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. <i>Diabetes Care</i> , <b>2017</b> , 40, 1034-1040	14.6	65
308	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 644-657	59.2	3789
307	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 723-732	59.2	349
306	Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions. <i>Diabetes Care</i> , <b>2017</b> , 40, e65-e66	14.6	14
305	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , <b>2017</b> , 187, 1-9	4.9	39
304	Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. <i>Small</i> , <b>2017</b> , 13, 1603028	11	24
303	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 370-380	16.2	98
302	HO-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. <i>ACS Nano</i> , <b>2017</b> , 11, 613-620	16.7	201
301	Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. <i>Lancet, The</i> , <b>2017</b> , 389, 369-380	40	158
300	5. Prevention or Delay of Type 2 Diabetes. <i>Diabetes Care</i> , <b>2017</b> , 40, S44-S47	14.6	58
299	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , <b>2017</b> , 40, 1763-1770	14.6	46
298	Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. <i>Diabetes Care</i> , <b>2017</b> , 40, 1787-1789	14.6	38

297	A survey of practices for the use of electronic health records to support research recruitment. <i>Journal of Clinical and Translational Science</i> , <b>2017</b> , 1, 246-252	0.4	35
296	The War Is Not Yet Won. <i>Diabetes Care</i> , <b>2017</b> , 40, 1152-1153	14.6	1
295	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. <i>Hypertension</i> , <b>2017</b> , 70, 907-914	8.5	10
294	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 839-848	59.2	599
293	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1228-1239	59.2	1017
292	Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2337-2348	59.2	224
291	Late-Breaking Science Abstracts From the American Heart Association's Scientific Sessions 2017 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2017. <i>Circulation</i> , <b>2017</b> , 136, e448-e467	16.7	10
290	Concerns About Conclusions of Self-monitoring of Blood Glucose-Reply. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1874-1875	11.5	
289	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2197-2208	59.2	25
288	Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1995-2002	59.2	2
287	Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol. <i>BMC Health Services Research</i> , <b>2017</b> , 17, 369	2.9	3
286	Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 78-86	6.7	43
285	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 164-170	14.6	39
284	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. <i>PeerJ</i> , <b>2017</b> , 5, e3187	3.1	9
283	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , <b>2016</b> , 39, 198-205	14.6	182
282	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2016</b> , 39, 1186-201	14.6	86
281	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1915-1924	14.6	32
280	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1834-1844	59.2	2547

279	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1798-9	59.2	48
278	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 311-22	59.2	3606
277	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , <b>2016</b> , 174, 103-10	4.9	70
276	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1321-31	59.2	654
275	New Insulins, Biosimilars, and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , <b>2016</b> , 18 Suppl 1, S43-55	8.1	4
274	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , <b>2016</b> , 39, 701-8	14.6	126
273	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 898-907	27.4	138
272	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 990-1004	27.4	122
271	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 603-10	14.6	90
270	Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. <i>Diabetes Care</i> , <b>2016</b> , 39, 92-100	14.6	63
269	Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk: A Cross-Sectional Study in Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , <b>2016</b> , 124, 104-11	8.4	71
268	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. <i>Frontiers in Genetics</i> , <b>2016</b> , 7, 138	4.5	2
267	A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 324-33	1.9	10
266	Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery (Adv. Mater. 16/2016). <i>Advanced Materials</i> , <b>2016</b> , 28, 3223	24	3
265	Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery. <i>Advanced Materials</i> , <b>2016</b> , 28, 3115-3121	24	138
264	More realistic power estimation for new user, active comparator studies: an empirical example. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 462-6	2.6	2
263	LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. <i>Diabetology and Metabolic Syndrome</i> , <b>2016</b> , 8, 37	5.6	7
262	Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. <i>International Journal of Obesity</i> , <b>2016</b> , 40, 1157-63	5.5	12

261	Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. <i>Diabetes Care</i> , <b>2016</b> , 39, 852-6	14.6	0
260	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 1013-23	2.8	11
259	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , <b>2016</b> , 59, 1645-54	10.3	67
258	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 126-35	16.2	161
257	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. <i>American Heart Journal</i> , <b>2016</b> , 179, 175-83	4.9	51
256	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1693-701	14.6	98
255	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 40-8	6.7	26
254	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 82-91	6.7	65
253	LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 477-86	6.7	15
252	Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 395-402	6.7	33
251	Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. <i>Pediatrics</i> , <b>2015</b> , 135, 424-34	7.4	193
250	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , <b>2015</b> , 38, 1687-93	14.6	499
249	Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l'étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER <sup>2</sup> ). <i>Medecine Des Maladies Metaboliques</i> , <b>2015</b> , 9, 316-328	0.1	1
248	Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 8260-5	11.5	509
247	The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1067-74	14.6	96
246	Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. <i>Journal of Pediatrics</i> , <b>2015</b> , 167, 627-32.e1-4	3.6	118
245	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 1181-8	14.6	138
244	Medications for type 2 diabetes: how will we be treating patients in 50 years?. <i>Diabetologia</i> , <b>2015</b> , 58, 1735-9	10.3	9



243	Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 505-10	6.7	11
242	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 995-1009	2.3	13
241	New insulins and insulin therapy. <i>Diabetes Technology and Therapeutics</i> , <b>2015</b> , 17 Suppl 1, S39-46	8.1	2
240	New medications for the treatment of diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2015</b> , 17 Suppl 1, S119-33	8.1	
239	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 2000-8	14.6	26
238	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 140-9	14.6	1906
237	Is insulin the most effective injectable antihyperglycaemic therapy?. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 145-51	6.7	19
236	Response to comment on Hempe et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. <i>Diabetes Care</i> <b>2015</b> ;38:1067-1074. <i>Diabetes Care</i> , <b>2015</b> , 38, e172-3	14.6	2
235	Efficacy, safety and tolerability of alogliptin in patients with type 2 diabetes: pooled findings from three randomized phase III trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 560-565	6.7	9
234	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 232-42	59.2	1739
233	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. <i>Clinical and Translational Science</i> , <b>2015</b> , 8, 623-31	4.9	2
232	One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 965-73	6.7	100
231	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2015</b> , 58, 429-42	10.3	496
230	Metabolomic characteristics of arsenic-associated diabetes in a prospective cohort in Chihuahua, Mexico. <i>Toxicological Sciences</i> , <b>2015</b> , 144, 338-46	4.4	29
229	Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2015</b> , 126, 62-76	0.9	4
228	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , <b>2015</b> , 10, 389-97	4.1	16
227	A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. <i>Pediatric Diabetes</i> , <b>2014</b> , 15, 110-7	3.6	79
226	Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents. <i>Journal of Pediatrics</i> , <b>2014</b> , 164, 1091-1098.e37	3.6	7

225	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1209-18	2.5	7
224	Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1721-8	14.6	179
223	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). <i>Diabetes Care</i> , <b>2014</b> , 37, 2926-33	14.6	189
222	Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1247-56	6.7	54
221	The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 874-9	3.2	16
220	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , <b>2014</b> , 37, 2647-59	14.6	48
219	Diabetes technology and therapy in the pediatric age group. <i>Diabetes Technology and Therapeutics</i> , <b>2014</b> , 16 Suppl 1, S100-9	8.1	
218	Immune intervention for type 1 diabetes, 2012-2013. <i>Diabetes Technology and Therapeutics</i> , <b>2014</b> , 16 Suppl 1, S85-91	8.1	1
217	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1016-27	6.7	180
216	We can change the natural history of type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2668-76	14.6	59
215	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 885-93	18.1	237
214	Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. <i>Biomacromolecules</i> , <b>2014</b> , 15, 3495-502	6.9	109
213	Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1065-9	6.7	11
212	Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. <i>Clinical Immunology</i> , <b>2014</b> , 153, 156-64	9	31
211	Cardiometabolic risk assessments by body mass index z-score or waist-to-height ratio in a multiethnic sample of sixth-graders. <i>Journal of Obesity</i> , <b>2014</b> , 2014, 421658	3.7	15
210	Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. <i>Environmental Health Perspectives</i> , <b>2014</b> , 122, 1088-94	8.4	40
209	GLP-1 receptor agonists and basal insulin in type 2 diabetes. <i>Lancet, The</i> , <b>2014</b> , 384, 2180-1	40	4
208	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 206-14	6.7	7

207	Knowledge, awareness, and behaviors of endocrinologists and dentists for the relationship between diabetes and periodontitis. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 106, 428-34	7.4	14
206	Effect of alogliptazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 1515-25	27.4	177
205	Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 324-33	11.5	112
204	LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. <i>Pancreas</i> , <b>2014</b> , 43, 1223-31	2.6	44
203	Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. <i>PLoS ONE</i> , <b>2014</b> , 9, e109433	3.7	4
202	Exposure to arsenic and cardiometabolic risk in Chihuahua, Mexico. <i>Arsenic in the Environment Proceedings</i> , <b>2014</b> , 526-530		
201	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet, The</i> , <b>2013</b> , 381, 117-24	4.0	397
200	Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 823-30.e5	4.9	162
199	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2013</b> , 36, 1779-88	14.6	114
198	Evaluation of the dual peroxisome proliferator-activated receptor $\alpha$ agonist alogliptazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. <i>American Heart Journal</i> , <b>2013</b> , 166, 429-34	4.9	34
197	Rising temperatures explain past immigration of the thermophilic oak-inhabiting beetle <i>Coraebus florentinus</i> (Coleoptera: Buprestidae) in south-west Germany. <i>Biodiversity and Conservation</i> , <b>2013</b> , 22, 1115-1131	3.4	24
196	Diabetes technology and treatment in the pediatric age group. <i>Diabetes Technology and Therapeutics</i> , <b>2013</b> , 15 Suppl 1, S107-16	8.1	2
195	Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(1) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 1293-7	3.5	74
194	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , <b>2013</b> , 36, 490-490	14.6	2
193	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 42-54	6.7	74
192	Low-density lipoprotein cholesterol versus particle number in middle school children. <i>Journal of Pediatrics</i> , <b>2013</b> , 163, 355-62	3.6	19
191	Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 3411-9	5.6	211
190	Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 2162-8	14.6	42

189	Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. <i>Molecular BioSystems</i> , <b>2013</b> , 9, 2785-97		35
188	Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. <i>Diabetes Care</i> , <b>2013</b> , 36, 3517-25	14.6	31
187	Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2254-61	14.6	173
186	Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 191ra82	17.5	112
185	Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. <i>Diabetes Care</i> , <b>2013</b> , 36, 2035-7	14.6	304
184	Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. <i>Journal of Human Genetics</i> , <b>2013</b> , 58, 378-83	4.3	12
183	Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. <i>Diabetes Care</i> , <b>2013</b> , 36, 429-35	14.6	47
182	Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1154-62	5.6	161
181	BMI change, fitness change and cardiometabolic risk factors among 8th grade youth. <i>Pediatric Exercise Science</i> , <b>2013</b> , 25, 52-68	2	15
180	Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 1-12	8	177
179	B-vitamins influence arsenic metabolism in Mexico. <i>FASEB Journal</i> , <b>2013</b> , 27, 1077.20	0.9	1
178	The role of obsessive-compulsive symptoms in the psychopathological profile of children with chronic tic disorder and attention-deficit hyperactivity disorder. <i>Zeitschrift für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , <b>2013</b> , 41, 163-9; quiz 170-1	1.8	1
177	Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. <i>Pediatric Obesity</i> , <b>2012</b> , 7, 230-9	4.6	32
176	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet, The</i> , <b>2012</b> , 379, 1489-97	40	260
175	Exploring salivary proteomes in edentulous patients with type 2 diabetes. <i>Molecular BioSystems</i> , <b>2012</b> , 8, 1304-10		50
174	Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 143-51	8.1	59
173	Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. <i>Diabetes Technology and Therapeutics</i> , <b>2012</b> , 14, 644-7	8.1	29
172	Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. <i>Diabetes Research and Clinical Practice</i> , <b>2012</b> , 96, e66-9	7.4	2

171	Strategies for multivessel revascularization in patients with diabetes. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2375-84	59.2	1140
170	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2012</b> , 35, 1364-79	14.6	2713
169	Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. <i>Diabetologia</i> , <b>2012</b> , 55, 1641-50	10.3	44
168	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2012</b> , 55, 1577-96	10.3	1108
167	Effect of nutrition changes on foods selected by students in a middle school-based diabetes prevention intervention program: the HEALTHY experience. <i>Journal of School Health</i> , <b>2012</b> , 82, 82-90	2.1	31
166	Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study. <i>Diabetes and Vascular Disease Research</i> , <b>2012</b> , 9, 124-30	3.3	8
165	The T1D Exchange clinic registry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 4383-9	5.6	328
164	Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. <i>Journal of Human Genetics</i> , <b>2012</b> , 57, 57-61	4.3	22
163	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , <b>2012</b> , 25, 154-171	1.9	22
162	Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 955-8	14.6	53
161	Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. <i>Diabetes Care</i> , <b>2012</b> , 35, 1008-14	14.6	88
160	Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists Association</i> , <b>2012</b> , 86, 82-90	1.1	3
159	Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. <i>Nature Reviews Endocrinology</i> , <b>2011</b> , 7, 67-8	15.2	16
158	Long-term effects of intensive glucose lowering on cardiovascular outcomes. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 818-28	59.2	732
157	Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. <i>Diabetic Medicine</i> , <b>2011</b> , 28, 715-23	3.5	26
156	Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. <i>Endocrine Practice</i> , <b>2011</b> , 17, 563-7	3.2	5
155	Effect of Secular Trends on a Primary Prevention Trial: The HEALTHY Study Experience. <i>Childhood Obesity</i> , <b>2011</b> , 7, 291-297	2.5	6
154	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 103-12	8	405

153	Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. <i>Endocrine Practice</i> , <b>2011</b> , 17, 906-13	3.2	37
152	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. <i>Lancet Neurology</i> , <b>2011</b> , 10, 969-77	24.1	356
151	Student public commitment in a school-based diabetes prevention project: impact on physical health and health behavior. <i>BMC Public Health</i> , <b>2011</b> , 11, 711	4.1	20
150	The effects of the HEALTHY study intervention on middle school student dietary intakes. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , <b>2011</b> , 8, 7	8.4	46
149	Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. <i>Diabetes Technology and Therapeutics</i> , <b>2011</b> , 13, 601-6	8.1	13
148	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 93, 1685-702	5.6	106
147	The DURABILITY of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. <i>Diabetes Care</i> , <b>2011</b> , 34, 249-55	14.6	37
146	Effects of rosiglitazone, glyburide, and metformin on $\beta$ cell function and insulin sensitivity in ADOPT. <i>Diabetes</i> , <b>2011</b> , 60, 1552-60	0.9	164
145	The safety of incretin-based therapies--review of the scientific evidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2027-31	5.6	130
144	Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. <i>Diabetes and Vascular Disease Research</i> , <b>2011</b> , 8, 237-40	3.3	92
143	HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulinitis to NOD-scid/ $\beta$ (null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells. <i>Diabetes</i> , <b>2011</b> , 60, 1726-33	0.9	25
142	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1659-68	27.4	721
141	Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 341-4	5.5	4
140	Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. <i>Diabetes Care</i> , <b>2011</b> , 34, 2403-5	14.6	86
139	Diabète et prédiabète: diagnostic et traitement <b>2011</b> , 319-326		
138	Ambient PM2.5 exposure up-regulates the expression of costimulatory receptors on circulating monocytes in diabetic individuals. <i>Environmental Health Perspectives</i> , <b>2011</b> , 119, 778-83	8.4	18
137	Type 2 Diabetes Mellitus <b>2011</b> , 1371-1435		18
136	Type 1 Diabetes Mellitus <b>2011</b> , 1436-1461		4

135	North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. <i>Journal of Dental Education</i> , <b>2011</b> , 75, 329-38	1.6	13
134	Univariate and bivariate linkage analysis identifies pleiotropic loci underlying lipid levels and type 2 diabetes risk. <i>Annals of Human Genetics</i> , <b>2010</b> , 74, 308-15	2.2	8
133	Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 983-90	14.6	331
132	A school-based intervention for diabetes risk reduction. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 443-53	59.2	251
131	Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. <i>Diabetes Care</i> , <b>2010</b> , 33, 1300-3	14.6	153
130	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. <i>Diabetes Care</i> , <b>2010</b> , 33, 1255-61	14.6	274
129	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1477-90	59.2	493
128	Effects of intensive blood-pressure control in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1575-85	59.2	2411
127	Screening for diabetes and prediabetes with proposed A1C-based diagnostic criteria: comment on Olson et al. <i>Diabetes Care</i> , <b>2010</b> , 33, e174; author reply e175	14.6	7
126	The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. <i>BMJ, The</i> , <b>2010</b> , 340, b4909	5.9	672
125	Effect of nateglinide on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1463-76	59.2	358
124	Effects of medical therapies on retinopathy progression in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 233-44	59.2	859
123	Recommendations for management of diabetes during Ramadan: update 2010. <i>Diabetes Care</i> , <b>2010</b> , 33, 1895-902	14.6	250
122	Effects of combination lipid therapy in type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1563-74	59.2	1940
121	Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 311-20	59.2	664
120	Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. <i>Lancet, The</i> , <b>2010</b> , 375, 1365-74	40	188
119	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 419-30	40	914
118	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. <i>Lancet, The</i> , <b>2010</b> , 376, 431-9	40	503

117	Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. <i>Diabetes Care</i> , <b>2010</b> , 33, 428-33	14.6	232
116	Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. <i>JAMA Ophthalmology</i> , <b>2010</b> , 128, 312-8		39
115	Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. <i>Particle and Fibre Toxicology</i> , <b>2010</b> , 7, 14	8.4	68
114	Management of Type 2 Diabetes Mellitus <b>2010</b> , 897-915		
113	DURABILITY of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 1007-13	14.6	103
112	Intensive glycemc control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the	14.6	500
111	Intensive glycemc control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. <i>Circulation</i> , <b>2009</b> , 119, 351-7	16.7	265
110	Clinical experience with continuous glucose monitoring in adults. <i>Diabetes Technology and Therapeutics</i> , <b>2009</b> , 11 Suppl 1, S93-S103	8.1	6
109	Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). <i>Neurology</i> , <b>2009</b> , 72, 1345-51	6.5	8
108	Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. <i>Clinical Trials</i> , <b>2009</b> , 6, 416-29	2.2	5
107	Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 1689-94	5.6	163
106	How do we define cure of diabetes?. <i>Diabetes Care</i> , <b>2009</b> , 32, 2133-5	14.6	696
105	Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 1547-55	27.4	547
104	Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). <i>Diabetes/Metabolism Research and Reviews</i> , <b>2009</b> , 25, 558-65	7.5	46
103	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2009</b> , 52, 17-30	10.3	541
102	The HEALTHY study: introduction. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S1-2	5.5	8
101	HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S4-20	5.5	60
100	Recruitment and retention strategies and methods in the HEALTHY study. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S21-8	5.5	28



99	Rationale, design and methods of the HEALTHY study nutrition intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S29-36	5.5	47
98	Rationale, design and methods of the HEALTHY study physical education intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S37-43	5.5	33
97	Rationale, design and methods of the HEALTHY study behavior intervention component. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S44-51	5.5	35
96	Social marketing-based communications to integrate and support the HEALTHY study intervention. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S52-9	5.5	46
95	Rationale, design and methods for process evaluation in the HEALTHY study. <i>International Journal of Obesity</i> , <b>2009</b> , 33 Suppl 4, S60-7	5.5	50
94	Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. <i>Diabetes Care</i> , <b>2009</b> , 32, 977-991	15.1	272
93	Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 193-203	14.6	2432
92	Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , <b>2009</b> , 32, 1224-30	14.6	691
91	International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 1327-34	14.6	2152
90	Exenatide for type 2 diabetes [Authors' reply]. <i>Lancet, The</i> , <b>2009</b> , 373, 122-123	4.0	
89	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet, The</i> , <b>2009</b> , 374, 39-47	4.0	1178
88	Development and validation of the Diabetes Numeracy Test (DNT). <i>BMC Health Services Research</i> , <b>2008</b> , 8, 96	2.9	113
87	Effects of intensive glucose lowering in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2545-59	59.2	5809
86	Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. <i>American Heart Journal</i> , <b>2008</b> , 155, 215-23	4.9	137
85	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. <i>American Heart Journal</i> , <b>2008</b> , 156, 623-32	4.9	72
84	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. <i>Lancet, The</i> , <b>2008</b> , 372, 1240-50	4.0	848
83	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-86	2.5	591
82	Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 173-5	14.6	232

81	Prevalence of the metabolic syndrome among a racially/ethnically diverse group of U.S. eighth-grade adolescents and associations with fasting insulin and homeostasis model assessment of insulin resistance levels. <i>Diabetes Care</i> , <b>2008</b> , 31, 2020-5	14.6	23
80	Are prescribing patterns of antidiabetic medications influenced by fears of litigation?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2008</b> , 4, 440-1		
79	Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. <i>Environmental Health Perspectives</i> , <b>2008</b> , 116, 1666-74	8.4	99
78	Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. <i>Diabetologia</i> , <b>2008</b> , 51, 8-11	10.3	80
77	A dead heat: target normal glucose levels in the intensive care unit--but with caution. <i>Diabetologia</i> , <b>2008</b> , 51, 909-10	10.3	13
76	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 275-286	2.5	217
75	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2007</b> , 30, 162-72	14.6	405
74	Glucose measurement: confounding issues in setting targets for inpatient management. <i>Diabetes Care</i> , <b>2007</b> , 30, 403-9	14.6	257
73	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 4i-20i	3	155
72	Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 21i-33i	3	385
71	Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , <b>2007</b> , 30, 2458-64	14.6	149
70	Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. <i>Diabetes Care</i> , <b>2007</b> , 30, 2000-1000	14.6	211
69	Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. <i>Circulation</i> , <b>2007</b> , 115, 114-26	16.7	552
68	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 139-53	3.5	235
67	A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2689-95	2.5	9
66	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2006</b> , 49, 1711-21	10.3	303
65	1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 1214-9	14.6	182
64	Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2006</b> , 29, 1963-72	14.6	935

63	The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes. <i>Yearbook of Endocrinology</i> , <b>2006</b> , 2006, 40-42		
62	The metabolic syndrome. <i>Lancet, The</i> , <b>2005</b> , 366, 1921-2; author reply 1923-4	4.0	19
61	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2005</b> , 34, 221-35	5.5	9
60	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. <i>Clinical Therapeutics</i> , <b>2005</b> , 27, 1181-95	3.5	84
59	Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. <i>Cardiology Clinics</i> , <b>2005</b> , 23, 211-220	2.5	1
58	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 2289-304	14.6	1574
57	The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , <b>2005</b> , 48, 1684-99	10.3	307
56	A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. <i>Diabetes Care</i> , <b>2005</b> , 28, 1547-54	14.6	664
55	Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. <i>Diabetes Care</i> , <b>2005</b> , 28, 337-442	14.6	260
54	Recommendations for management of diabetes during Ramadan. <i>Diabetes Care</i> , <b>2005</b> , 28, 2305-11	14.6	175
53	Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. <i>British Journal of Psychiatry</i> , <b>2004</b> , 47, S94-101	5.4	14
52	The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2004</b> , 6, 133-56	6.7	110
51	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 2628-35	14.6	1088
50	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 215-23	2.5	42
49	Prevention or delay of type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27 Suppl 1, S47-54	14.6	108
48	40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. <i>Diabetologia</i> , <b>2004</b> , 47, A1-A464	10.3	34
47	Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. <i>Diabetes Care</i> , <b>2003</b> , 26, 2700-1	14.6	1
46	The insulin resistance syndrome and coronary artery disease. <i>Coronary Artery Disease</i> , <b>2003</b> , 14, 335-48	1.4	43

45	Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. <i>Diabetes Technology and Therapeutics</i> , <b>2003</b> , 5, 355-63	8.1	129
44	A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. <i>Journal of Clinical Epidemiology</i> , <b>2003</b> , 56, 164-70	5.7	167
43	Follow-up report on the diagnosis of diabetes mellitus. <i>Diabetes Care</i> , <b>2003</b> , 26, 3160-7	14.6	2996
42	Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3082-9	5.6	487
41	Glitazones and heart failure: critical appraisal for the clinician. <i>Circulation</i> , <b>2003</b> , 108, e57	16.7	8
40	Should postprandial glucose be routinely measured and treated to a particular target? No!. <i>Diabetes Care</i> , <b>2003</b> , 26, 1615-8	14.6	17
39	Autoimmune endocrine disease. <i>Current Opinion in Immunology</i> , <b>2002</b> , 14, 760-4	7.8	25
38	What we think and what we know. <i>Diabetes Care</i> , <b>2002</b> , 25, 1876-8	14.6	5
37	Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1568-76		432
36	The prevention or delay of type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 742-9	14.6	452
35	Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1877-81	15.1	64
34	Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63 Suppl 4, 37-41	4.6	6
33	Treatment of postprandial hyperglycemia in type 2 diabetes. <i>Postgraduate Medicine</i> , <b>2001</b> , 110, 14-9	3.7	
32	Panel discussion on achieving glycemic control. <i>Postgraduate Medicine</i> , <b>2001</b> , 110, 20-5	3.7	
31	Combining insulin and oral agents. <i>American Journal of Medicine</i> , <b>2000</b> , 108 Suppl 6a, 23S-32S	2.4	46
30	The use of insulin alone and in combination with oral agents in type 2 diabetes. <i>Primary Care - Clinics in Office Practice</i> , <b>1999</b> , 26, 931-50	2.2	7
29	Management of glycemia in type 2 diabetes. <i>Clinical Cornerstone</i> , <b>1998</b> , 1, 39-57		3
28	The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. <i>Clinical Therapeutics</i> , <b>1998</b> , 20, 257-69	3.5	26

27	Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. <i>Diabetes Care</i> , <b>1998</b> , 21, 1455-61	14.6	73
26	The case for a role for postprandial glucose monitoring in diabetes management. <i>Journal of Family Practice</i> , <b>1998</b> , 47, S29-36	0.2	5
25	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1996</b> , 37, 569-73	3.5	4
24	The GENNID Study. A resource for mapping the genes that cause NIDDM. <i>Diabetes Care</i> , <b>1996</b> , 19, 864-72	4.6	58
23	Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. <i>Journal of Clinical Investigation</i> , <b>1994</b> , 93, 578-85	15.9	113
22	Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. <i>Transplantation</i> , <b>1993</b> , 55, 186-92	1.8	37
21	The soluble interleukin-6 receptor is generated by shedding. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 473-80	6.1	410
20	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. <i>Diabetes</i> , <b>1992</b> , 41, 1436-45	0.9	53
19	Human intestinal glucose transporter expression and localization of GLUT5. <i>American Journal of Physiology - Cell Physiology</i> , <b>1992</b> , 262, C795-800	5.4	147
18	Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. <i>Journal of Biological Chemistry</i> , <b>1992</b> , 267, 11673-6	5.4	44
17	Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. <i>Diabetes</i> , <b>1992</b> , 41, 1436-1445	0.9	12
16	Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCP. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 4313	20.1	5
15	Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. <i>Journal of Clinical Investigation</i> , <b>1991</b> , 88, 1323-30	15.9	70
14	Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. <i>Diabetes</i> , <b>1991</b> , 40, 1712-1718	0.9	12
13	Molecular biology of mammalian glucose transporters. <i>Diabetes Care</i> , <b>1990</b> , 13, 198-208	14.6	755
12	Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. <i>Journal of Biological Chemistry</i> , <b>1989</b> , 264, 7776-9	5.4	307
11	T-cell antigen receptor alpha chain polymorphisms in insulin-dependent diabetes. <i>Journal of Autoimmunity</i> , <b>1988</b> , 1, 389-97	15.5	1
10	The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. <i>Science</i> , <b>1986</b> , 231, 733-5	33.3	383

9	Autoimmune endocrine disease. <i>Vitamins and Hormones</i> , <b>1985</b> , 42, 253-314	2.5	4
8	Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats. <i>Journal of Experimental Medicine</i> , <b>1985</b> , 162, 444-58	16.6	15
7	Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. <i>Journal of Experimental Medicine</i> , <b>1984</b> , 159, 1629-36	16.6	88
6	Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. <i>Diabetologia</i> , <b>1984</b> , 27 Suppl, 77-9	10.3	12
5	Specific class II histocompatibility gene polymorphism in BB rats. <i>Diabetes</i> , <b>1984</b> , 33, 700-703	0.9	2
4	Lymphocyte abnormalities in the BB rat. <i>Metabolism: Clinical and Experimental</i> , <b>1983</b> , 32, 83-6	12.7	27
3	Disordered cellular immunity in type I diabetes of man and the BB rat. <i>Survey of Immunologic Research</i> , <b>1982</b> , 1, 339-51		5
2	Kallikrein-induced uterine contraction independent of kinin formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1981</b> , 78, 6154-7	11.5	33
1	The role of the human placenta in the transfer and metabolism of insulin. <i>Journal of Clinical Investigation</i> , <b>1962</b> , 41, 29-41	15.9	76